LEXX

Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and DehydraTECH-semaglutide ("DHT-SEMA") glucagon-like peptide-1 ("GLP-1") compositions to explore the potential for additional improved performance, as well as stake new intellectual property ("IP") claims.Lexaria has already filed 3 new patent applicat

EFFECT - Lexaria Bioscience Corp. (0001348362) (Filer)

424B3 - Lexaria Bioscience Corp. (0001348362) (Filer)

Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.Lexaria's DehydraTECH™ technology is currently being evaluated both by Lexaria and pharmaceutical industry partners for use within the rapidly growing GLP-1 receptor agonist and weight-loss/diabetes drug industries. Those industry segments were valued at $62.8 billion in 2025 and are estimated to grow to $73.4 bill

S-3 - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share. The combined net proceeds from these two items totaled US$7.9 million. With only 2.1 million shares currently issued and outstanding, the US$7.9 million in fresh new capital plus our pre-existing cash balance represents approximately US$4.60/share in current cash on hand."Despite the positive achievements we have recently reported across

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.9

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City.Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link.Event Details:Conference: 28th Annual H.C. Wainwright Global Investment ConferenceDate: September 14-16th, 2026Accredited inve

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.Lexaria strategically performed its previous 12-week chronic GLP-1-H24-4 Study in Australia, fully aware of certain potential tax advantages in doing so. Lexaria's 2025 application for the cash rebate was accepted

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry studyProprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluatedFindings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK")

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1 molecule which will then be processed with Lexaria's

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the "Reverse Split").The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's ("Nasdaq") minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) (the "Minimum Price Rule"). The Reverse Split is also being performed in an effort to stabilize uncertain stock condit

10-Q - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention ("BIO") in San Diego, CA."Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies," said Richard Christopher, CEO of Lexaria Bioscience Corp. "We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent o

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's® ("Novo") commercially available Wegovy® tablets, over a 5-week duration (the "Study").Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 ("GLP-1") studies such as Human Study #4 (GLP-1-H24-4), combined with pharmacokinetic ("PK") performance that matches or exceeds

Potentially Valuable Novel Compositions Being InvestigatedLexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following update on Animal Study #1 (GLP-1-A26-1) that is evaluating a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").The Study is on schedule and dosin

More People Than Ever Taking GLP-1 Drugs for Weight LossGrowing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update.On June 7th, Novo Nordisk® ("Novo") announced that over three million Wegovy® pill prescriptions had been filled since its initial launch on January 5, 2026, in what they call "one of the strongest US pharmaceutical launches by volume on record". They also offered the information that 82% of those prescriptions went to peopl

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECHTM performance as well as potentially stake new intellectual property claims.Retatrutide is one of Eli Lilly and Company's® leading next-generation GLP-1 drugs undergoi

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development ("BD") program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference."We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference," said Ri